Catherine Orrell

Summary

Affiliation: University of Cape Town
Country: South Africa

Publications

  1. ncbi Adherence is not a barrier to successful antiretroviral therapy in South Africa
    Catherine Orrell
    Diana, Princess of Wales HIV Research Unit, Somerset Hospital, University of Cape Town, South Africa
    AIDS 17:1369-75. 2003
  2. ncbi Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited
    Catherine Orrell
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    Antivir Ther 12:83-8. 2007
  3. pmc Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy
    Catherine Orrell
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa
    Pediatr Infect Dis J 32:644-7. 2013
  4. pmc Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Catherine Orrell
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Antivir Ther 16:527-34. 2011
  5. pmc HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme
    Catherine Orrell
    Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    Antivir Ther 14:523-31. 2009
  6. ncbi Antiretroviral adherence in a resource-poor setting
    Catherine Orrell
    Desmond Tutu HIV Centre, IIDMM, Werner Beit Building North, Medical School, Anzio Road, Observatory, Cape Town 7925, South Africa
    Curr HIV/AIDS Rep 2:171-6. 2005
  7. pmc Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression
    Mweete D Nglazi
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, and the Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    PLoS ONE 8:e57907. 2013
  8. ncbi Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 43:770-6. 2006
  9. ncbi When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study
    Motasim Badri
    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine, University of Cape Town, South Africa
    Antivir Ther 11:63-72. 2006
  10. pmc Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa
    Mweete D Nglazi
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    J Acquir Immune Defic Syndr 56:e1-8. 2011

Detail Information

Publications29

  1. ncbi Adherence is not a barrier to successful antiretroviral therapy in South Africa
    Catherine Orrell
    Diana, Princess of Wales HIV Research Unit, Somerset Hospital, University of Cape Town, South Africa
    AIDS 17:1369-75. 2003
    ..To determine adherence of an indigent African HIV-infected cohort initiating antiretroviral therapy (ART); to identify predictors of incomplete adherence (< 95%) and virologic failure (> 400 HIV RNA copies/ml)...
  2. ncbi Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited
    Catherine Orrell
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    Antivir Ther 12:83-8. 2007
    ....
  3. pmc Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy
    Catherine Orrell
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa
    Pediatr Infect Dis J 32:644-7. 2013
    ..Nineteen percent had wild-type virus. Appropriate antiretroviral therapy sequencing in sub-Saharan African children is essential for prolong treatment options. ..
  4. pmc Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Catherine Orrell
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Antivir Ther 16:527-34. 2011
    ..Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations...
  5. pmc HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme
    Catherine Orrell
    Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    Antivir Ther 14:523-31. 2009
    ..This study aimed to evaluate HIV type-1 (HIV-1) drug resistance pretreatment and in those failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in South Africa...
  6. ncbi Antiretroviral adherence in a resource-poor setting
    Catherine Orrell
    Desmond Tutu HIV Centre, IIDMM, Werner Beit Building North, Medical School, Anzio Road, Observatory, Cape Town 7925, South Africa
    Curr HIV/AIDS Rep 2:171-6. 2005
    ..Major factors contributing to adherence or nonadherence are whether the drug is accessed for free or is self-funded, patient preparedness for use of ART, stigmatization related to being HIV-positive, and ease of use of regimen...
  7. pmc Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression
    Mweete D Nglazi
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, and the Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    PLoS ONE 8:e57907. 2013
    ..To determine the proportion, characteristics and outcomes of patients who transfer-out from an antiretroviral therapy (ART) service in a South African township...
  8. ncbi Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 43:770-6. 2006
    ..Understanding the determinants of key outcome measures--including death and nondeath losses--would assist in program evaluation and development...
  9. ncbi When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study
    Motasim Badri
    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine, University of Cape Town, South Africa
    Antivir Ther 11:63-72. 2006
    ..However, cost-effectiveness of initiating treatment at different CD4 count thresholds has not been explored in resource-poor settings...
  10. pmc Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa
    Mweete D Nglazi
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    J Acquir Immune Defic Syndr 56:e1-8. 2011
    ..To assess sustainability of programmatic outcomes in a community-based antiretroviral therapy (ART) service in South Africa during 7 years of scale-up...
  11. ncbi Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa
    Linda Gail Bekker
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town
    S Afr Med J 96:315-20. 2006
    ..Despite rapid expansion of antiretroviral therapy (ART) in sub-Saharan Africa there are few longitudinal data describing programme performance during rapid scale-up...
  12. pmc Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa
    Katharina Kranzer
    Department of Medicine, Faculty of Health Sciences, The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    PLoS ONE 5:e13801. 2010
    ..Programme reports typically focus on loss to follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of individuals prior to starting ART...
  13. pmc Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors
    Katharina Kranzer
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, South Africa
    J Acquir Immune Defic Syndr 55:e17-23. 2010
    ..To investigate antiretroviral treatment (ART) interruption in a long-term treatment cohort in South Africa...
  14. pmc Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, South Africa
    AIDS 23:335-42. 2009
    ..To determine the relationship between mortality risk and the CD4 cell response to antiretroviral therapy (ART)...
  15. pmc Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial
    Ian Sanne
    Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    Lancet 376:33-40. 2010
    ..We compared outcomes of nurse versus doctor management of ART care for HIV-infected patients...
  16. pmc Healthcare utilization of patients accessing an African national treatment program
    Guy Harling
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    BMC Health Serv Res 7:80. 2007
    ..Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced...
  17. pmc Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa
    Lisa Noelle Ncaca
    Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa
    PLoS ONE 6:e23088. 2011
    ..Understanding of the impact of non-structured treatment interruption (TI) and variation in tablet-taking on failure of first-line antiretroviral therapy (ART) is limited in a resource-poor setting...
  18. ncbi Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Cape Town, South Africa
    AIDS 19:2141-8. 2005
    ..To determine rates, risk factors and causes of death among patients accessing a community-based antiretroviral treatment (ART) programme both prior to and following initiation of treatment...
  19. pmc Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment
    Richard Kaplan
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    AIDS 22:1679-81. 2008
    ..This finding highlights the need for programmatic interventions to address retention in care for this patient population...
  20. ncbi Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines
    Motasim Badri
    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine, University of Cape Town, Observatory, South Africa
    AIDS 18:1159-68. 2004
    ....
  21. pmc Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets
    Eric H Decloedt
    Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
    Antimicrob Agents Chemother 55:3195-200. 2011
    ..Doubling the dose of the tablet formulation of LPV/r overcomes induction by rifampin. Less hepatotoxicity occurred in our cohort of HIV-infected participants than was reported in healthy-volunteer studies...
  22. pmc Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir
    Christine Njuguna
    Desmond Tutu HIV Centre, Institute for Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    PLoS ONE 8:e63596. 2013
    ..This study describes the patterns and risk factors for drug changes of these antiretroviral drugs in adults...
  23. pmc Low Prevalence of Liver Disease but Regional Differences in HBV Treatment Characteristics Mark HIV/HBV Co-Infection in a South African HIV Clinical Trial
    Prudence Ive
    Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    PLoS ONE 8:e74900. 2013
    ..In this study, we analysed data from the CIPRA-SA 'Safeguard the household study' in order to assess baseline HBV characteristics in HIV/HBV co-infection participants prior to antiretroviral therapy (ART) initiation...
  24. pmc Effect of caregivers' depression and alcohol use on child antiretroviral adherence in South Africa
    Heather B Jaspan
    Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    AIDS Patient Care STDS 25:595-600. 2011
    ..99). Pediatric adherence is affected by caregiver alcohol use, but caregiver relationship to the child is most important. This small study suggests that interventions should aim to keep mothers healthy and alive, as well as alcohol-free...
  25. pmc Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy
    Catherine Orrell
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town 7925, South Africa
    AIDS Res Treat 2011:469127. 2011
    ..While 67% of those who experience initial virological breakthrough resuppress after an adherence intervention, these individuals are significantly less likely be retained in care than those who remain virologically suppressed throughout...
  26. ncbi Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings
    Stephen D Lawn
    Lancet Infect Dis 6:385-6; author reply 387-8. 2006
  27. ncbi Antiretroviral therapy in a community clinic--early lessons from a pilot project
    Linda Gail Bekker
    HIV Research Unit, University of Cape Town, Provincial Administration of the Western Cape
    S Afr Med J 93:458-62. 2003
    ..To report on operational and clinical problems encountered during the first 6 months of a community-based antiretroviral therapy (ART) programme...
  28. pmc Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS Med 5:e148. 2008
    ..We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland...
  29. ncbi Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme
    Stephen D Lawn
    AIDS 19:2050-2. 2005